Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients. 

Learning Objectives

  • Recognize when basal insulin is the preferred option for improving glycemic control in patients with type 2 diabetes mellitus (T2DM).
  • Consider basal insulin characteristics in the context of patient needs and preferences when identifying treatment options for patients with T2DM. 
  • Initiate and titrate basal insulin therapy to achieve individualized blood glucose (BG) targets in patients with T2DM
  • Use BG data to identify glucose control challenges and adjust therapy for the safe and effective use of basal insulin therapy in patients with T2DM.


James R. Gavin, III, MD, PhD

Clinical Professor of Medicine
Emory University School of Medicine
Chief Medical Officer
Healing Our Village, Inc.
Atlanta, GA 

John E. Anderson, MD

Past President
The Frist Clinic
Nashville, TN 


The following financial relationships have been disclosed by faculty: 

James R. Gavin III, MD, PhD
Advisory Board for Abbott; Intarcia Therapeutics, Inc.; Janssen Scientific Affairs, LLC; and Novo Nordisk Inc. Consultant for Abbott; Intarcia Therapeutics, Inc.; and Novo Nordisk Inc. Services Provided for Promotional Purposes (not for CME/CE Services) for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Janssen Scientific Affairs, LLC; Novo Nordisk Inc.; and Sanofi US. Speaker's Bureau for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Janssen Scientific Affairs, LLC; Novo Nordisk Inc.; and Salix Pharmaceuticals, Inc. 

John E. Anderson, MD
Advisory Board for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Scientific Affairs, LLC; Lilly USA, LLC; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk Inc.; and Sanofi US. Consultant for AstraZeneca; Janssen Scientific Affairs, LLC; Lilly USA, LLC; Novo Nordisk Inc.; and Sanofi US. Speaker's Bureau for AstraZeneca; Janssen Scientific Affairs, LLC; Lilly USA, LLC; Novo Nordisk Inc.; and Sanofi US. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This program has been approved for 0.28 contact hour of continuing education, including 0 hour of pharmacology. 

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Commercial Supporter

Novo Nordisk Inc.

Education Partner

Institute for Medical and Nursing Education, Inc.

Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.